1. AHRO : Austin Health Research Online
  2. Austin Health research
  3. Journal articles
Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/23870
Full metadata record
DC FieldValueLanguage
dc.contributor.authorLewis, Katharine L-
dc.contributor.authorChin, Collin K-
dc.contributor.authorManos, Kate-
dc.contributor.authorCasey, John-
dc.contributor.authorHamad, Nada-
dc.contributor.authorCrawford, Julie-
dc.contributor.authorHo, Shir-Jing-
dc.contributor.authorIssa, Samar-
dc.contributor.authorGrigg, Andrew P-
dc.contributor.authorWood, Peter-
dc.contributor.authorGandhi, Maher K-
dc.contributor.authorDo, Bryan-
dc.contributor.authorNastoupil, Loretta-
dc.contributor.authorHawkes, Eliza A-
dc.contributor.authorCheah, Chan Y-
dc.date2020-07-16-
dc.date.accessioned2020-07-27T05:09:34Z-
dc.date.available2020-07-27T05:09:34Z-
dc.date.issued2021-03-
dc.identifier.citationBritish Journal of Haematology 2020; 192(6): 1049-1053en
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/23870-
dc.description.abstractPrimary and secondary central nervous system lymphomas (PCNSL/SCNSL) are aggressive rare malignancies with dismal outcomes. Encouraging data have emerged from Phase I/II clinical trials treating relapsed/refractory PCNSL/SCNSL with ibrutinib. We analysed 33 patients who received ibrutinib, alone or with other therapies, for PCNSL (n = 9) or SCNSL (n = 24). The objective response rate was 58% (complete response 55%). The median progression-free survival and overall survival for patients with PCNSL were both 3·1 months; for SCNSL, 10·2 and 11·5 months respectively. Only one invasive fungal infection was observed, despite concurrent or recent use of dexamethasone 8-16 mg daily in 14 patients (42%). Ibrutinib has encouraging activity in these aggressive malignancies.en
dc.language.isoeng
dc.subjectBTK inhibitoren
dc.subjectcentral nervous systemen
dc.subjectibrutiniben
dc.subjectlymphomaen
dc.subjectnovelen
dc.titleIbrutinib for central nervous system lymphoma: the Australasian Lymphoma Alliance/MD Anderson Cancer Center experience.en
dc.typeJournal Articleen
dc.identifier.journaltitleBritish Journal of Haematologyen
dc.identifier.affiliationDepartment of Haematology, Middlemore Hospital, Auckland, New Zealanden
dc.identifier.affiliationDepartment of Haematology, Sir Charles Gairdner Hospital, Nedlands, WA, Australiaen
dc.identifier.affiliationMedical School, University of Western Australia, Nedlands, WA, Australiaen
dc.identifier.affiliationLinear Clinical Research, Nedlands, WA, Australiaen
dc.identifier.affiliationClinical Haematologyen
dc.identifier.affiliationDepartment of Haematology, The Townsville Hospital, Townsville, QLD, Australiaen
dc.identifier.affiliationDepartment of Haematology, St Vincent's Hospital, UNSW, Sydney, NSW, Australiaen
dc.identifier.affiliationDepartment of Lymphoma/Myeloma, MD Anderson Cancer Center, Houston, TX, USAen
dc.identifier.affiliationUniversity of Melbourne, Melbourne, VIC, Australiaen
dc.identifier.affiliationDepartment of Haematology, Princess Alexandra Hospital, Brisbane, QLD, Australiaen
dc.identifier.affiliationDepartment of Haematology, St George Hospital, Sydney, NSW, Australiaen
dc.identifier.affiliationDepartment of Haematology, Eastern Health, Box Hill, VIC, Australiaen
dc.identifier.affiliationDepartment of Haematology, Pathwest Laboratory Medicine, Perth, WA, Australiaen
dc.identifier.doi10.1111/bjh.16946en
dc.type.contentTexten
dc.identifier.orcid0000-0003-0549-5877en
dc.identifier.orcid0000-0001-6880-2876en
dc.identifier.orcid0000-0001-7929-1450en
dc.identifier.orcid0000-0001-5743-3171en
dc.identifier.orcid0000-0003-1000-5393en
dc.identifier.orcid0000-0002-2094-3191en
dc.identifier.orcid0000-0001-7988-1565en
dc.identifier.pubmedid32677095
dc.type.austinJournal Article
local.name.researcherGrigg, Andrew P
item.openairetypeJournal Article-
item.cerifentitytypePublications-
item.grantfulltextnone-
item.fulltextNo Fulltext-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.languageiso639-1en-
crisitem.author.deptClinical Haematology-
crisitem.author.deptOlivia Newton-John Cancer Wellness and Research Centre-
crisitem.author.deptClinical Haematology-
crisitem.author.deptClinical Haematology-
crisitem.author.deptOlivia Newton-John Cancer Wellness and Research Centre-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

44
checked on Nov 28, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.